Traws Pharma Inc (TRAW) Stock Analysis

AI analysis of Traws Pharma Inc (TRAW)

Sell

Traws Pharma Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $0.2271, which is down 82.92% year-to-date, indicating a severe decline in value. Additionally, the RSI is at 11.257, suggesting the stock is heavily oversold, but this could also indicate a lack of buying interest. The company has a forward P/E of 0, reflecting uncertainty about future earnings, and a gross margin of 0% in recent quarters, showing no profitability. The main risk is the delayed study for its lead flu drug, which has already caused a 28% drop in after-hours trading, highlighting the volatility and uncertainty surrounding the stock.

Valuation Metrics

The current forward P/E ratio for Traws Pharma Inc (TRAW) is 0.00, compared to its 5-year average forward P/E of -1.08.

Forward P/E

Fair

5Y Average P/E

-1.08

Current P/E

0.00

Overvalued

3.49

Undervalued

-5.65

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.51

Current EV/EBITDA

0.00

Overvalued

5.66

Undervalued

-4.64

Forward P/S

Undervalued

5Y Average P/S

73.86

Current P/S

0.00

Overvalued

122.77

Undervalued

24.94

Alphio AI Price Scenarios for TRAW

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TRAW

$1.17

Scenario price

B

Base

Base · 50%TRAW

$1.15

Scenario price

B

Bear

Bear · 25%TRAW

$0.90

Scenario price

TRAW FAQ — answered by Alphio AI

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology. It operates in the Healthcare sector.

Traws Pharma Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $0.2271, which is down 82.92% year-to-date, indicating a severe decline in value. Additionally, the RSI is at 11.257, suggesting the stock is heavily oversold, but this could also indicate a lack of buying interest. The company has a forward P/E of 0, reflecting uncertainty about future earnings, and a gross margin of 0% in recent quarters, showing no profitability. The main risk is the delayed study for its lead flu drug, which has already caused a 28% drop in after-hours trading, highlighting the volatility and uncertainty surrounding the stock.